热门新闻
联系我们
当前位置:主页 > 热门新闻 >
热门新闻

WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer

时间:2019-02-01 作者:AG88

SHANGHAI, May 12 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX) today announced that it has appointed Hao Zhou as Chief Financial Officer, effective immediately.

(Logo: /uploads/allimg/180930/20180930111347cz203sxyu4l38615.jpg )

Mr. Zhou joined the company in May 2009 as Vice President of Finance. His initial responsibilities included financial planning and analysis, ERP system enhancement, tax, and treasury, and he has assumed increasing responsibilities for overall financial operations. As Chief Financial Officer, Hao will report to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Prior to joining WuXi PharmaTech, Mr. Zhou worked for eleven years at General Electric. He held positions of increasing responsibility in financial planning and analysis, enterprise resource planning (ERP) systems, accounting and internal control at GE and was based in Tokyo, London, Shanghai, and several locations in the United States. Most recently he was Finance Director, Greater China, for GE Healthcare Medical Diagnostics and Life Sciences. He also served as an auditor for GE Corporate.

"I am very pleased to announce Hao's promotion to Chief Financial Officer," commented Dr. Ge Li. "With his strong financial background and work ethic, Hao has done an excellent job managing our company's financial operations.

"I also want to thank Ed Hu for serving as a very effective acting Chief Financial Officer for the past year, in addition to his other responsibilities. Hao's appointment allows Ed to concentrate on building our operations and growing our business as our Chief Operating Officer."

Edward Hu, Chief Operating Officer, commented, "I have worked closely with Hao over the past year. He has demonstrated the keen intellect, strong financial expertise, and diligence required of a Chief Financial Officer. I look forward to working with him as WuXi continues to build its capabilities."

Dr. Li concluded, "We look forward to Hao's financial leadership as our growing company broadens its platform of R&D services for the world's pharmaceutical, biotechnology, and medical device companies and prepares to combine with Charles River Laboratories."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. On April 26, 2010, WuXi and Charles River Laboratories announced that the boards of both companies had reached an agreement for the two companies to combine operations, creating the first global contract research organization offering fully integrated early-stage drug development services to clients worldwide. For more information, please visit: http://www.wuxiapptec.com .

For more information, please contact:

Stephanie Liu (for the media)

Tel: +86-21-5046-4362

Email: pr@wuxiapptec.com

Ronald Aldridge (for investors)

Tel: +1-201-585-2048

Email: Ron_Aldridge@wuxiapptec.com

本文源自: AG环亚官网

上一篇:Winner Medical Group Inc. Announces Closing of $8.4 Million

下一篇:没有了